Glenn Boehnlein
Vice President, Chief Financial Officer at Stryker
Thanks, Jason. Today, I will focus my comments on our second quarter financial results and the related drivers. Our detailed financial results have been provided in today's press release.
Our organic sales growth was 6.1% in the quarter. The second quarter's average selling days were in line with 2021. The impact from pricing in the quarter was unfavorable 1.4%. Foreign currency had a 3% unfavorable impact on sales. Despite a challenging comparable versus 2021, our organic sales growth has been solid and was led by double-digit performances in our endoscopy and instruments businesses as well as strong growth in our international businesses. Our sales growth has been somewhat constrained by the continued supply chain challenges and electronic component shortages, especially impacting the capital products in our MedSurg businesses, primarily in our medical business.
Our capital order book continues to be very robust as demand from our customers continues to be strong. In the quarter, US organic sales growth was 4.7%. International organic sales growth was 9.7%, impacted by positive sales momentum across most of our international markets, specifically, emerging markets, Canada, Japan and Europe somewhat offset by lingering COVID impacts in Australia and China. Our adjusted EPS of $2.25 in the quarter was in line with 2021, driven by our sales momentum and favorable adjusted tax rate, offset by gross margin challenges and the impact of foreign currency exchange. Our second quarter EPS was negatively impacted by foreign currency exchange of $0.05 versus 2021.
Now I will provide some highlights around our segment performance. In the quarter, MedSurg and Neurotechnology had constant currency sales growth of 10.6% with organic sales growth of 7.9%, which included 7.2% of US organic growth and 9.9% of international organic growth. Instruments had US organic sales growth of 12.1%, led by double-digit growth in our orthopedic instruments and surgical technologies businesses. From a product perspective, sales growth was highlighted by double-digit growth in power tools, surg account, irrigation, smoke evacuation and Steri-Shield.
Endoscopy had US organic sales growth of 15.4%, reflecting very strong performances across all of their portfolio, including video products and double-digit growth of our Communications and Sports Medicine businesses. Medical, which includes our recently acquired Vocera business had a US organic sales decline of 2.4%, driven by the aforementioned supply chain challenges, primarily impacting our emergency care products. Medical stage and acute care businesses posted double-digit organic growth. During the quarter, we also saw significant growth in orders for our beds and emergency care products, driven by very strong customer demand.
Our US Neurovascular business posted an organic decline of 1.8%, driven by a strong double-digit comparable in 2021 as well as competitive pressures, disruptions due to hospital staffing shortages and softer market conditions in part because of supply shortages of contrast used in procedures. The US Neuro Cranial business posted organic sales growth of 9.4%, which included solid growth in our ENT navigation, balloon dilation and neuro products. Internationally, MedSurg and Neurotechnology had organic sales growth of 9.9%, reflecting double-digit growth in the Endoscopy, Neurovascular and Neuro Cranial businesses somewhat offset by medical. Geographically, this included strong performances in Japan and emerging markets.
Orthopaedics and Spine had both constant currency and organic sales growth of 3.9%, which included organic growth of 1.6% in the US and 9.5% internationally. This reflects the impact of strong international growth and solid growth in our hip, knee and extremity businesses. Our US hips business grew 4.5% organically, reflecting strong primary hip growth reflected by the recent launch of our Insignia Hip Stem and continued procedural growth. Our US Knee business grew 5.3% organically, reflecting our market leading position in robotic knee procedures.
Our US Trauma and Extremities business grew 3.1% organically against a significant comparable in 2021. This growth was led by double-digit growth in our upper extremities somewhat offset by softness in the trauma market. Our US Spine business declined 3.6% organically, reflecting a slightly slower scoliosis season, partially offset by solid performance in our Enabling Technology business.
Our US Other Ortho declined organically by 13.8%, primarily driven by the impact related to the aforementioned deal mix changes of Mako installations in the quarter. Internationally, Orthopaedics and Spine grew 9.5% organically, which reflects the strong momentum in Europe as procedural volumes improved as well as strong performances in Japan, Canada and India somewhat offset by COVID-related volatility in Australia and Korea.
Now, I will focus on operating highlights in the second quarter. Our adjusted gross margin of 63.3% was unfavorable approximately 270 basis points from the second quarter of 2021. Compared to 2021, our gross margin was adversely impacted by the purchases of electronic components at premium prices on the spot market and other inflationary pressures primarily related to labor, steel and transportation costs, as well as operational efficiencies due to the component shortages. We expect these adverse impacts to continue throughout 2022.
We expect Q3 gross margin to be similar to Q2. Q4 should see some improvement and the full-year gross margin compared to 2021 will be negatively impacted by approximately 200 basis points. Adjusted R&D was 7.2% of sales, which represents a 60 basis point increase from 2021. This reflects our continued commitment to innovation funding and the related future growth it will provide. Our adjusted SG&A was 32.4% of sales, which was 100 basis points lower than 2021. This reflects continued cost discipline somewhat offset by the ramping of certain prioritized expenses and hiring that support future growth.
In summary for the quarter, our adjusted operating margin was 23.7% of sales, which was approximately 220 basis points unfavorable to the second quarter of 2021. This performance is primarily driven by the aforementioned inflationary impacts, resulting in gross margin challenges and the net negative impact resulting from foreign currency. Adjusted other income and expense decreased from 2021, primarily resulting from an equity investment gain and favorable interest income. We anticipate a normalized run rate of adjusted OI&E to be approximately $70 million per quarter for the remainder of 2022.
Our second quarter had an adjusted effective tax rate of 13.9%, reflecting the impact of geographic mix and certain discrete tax items. We now expect our full year adjusted effective tax rate to be in the range of 14.5% to 15%, which is consistent with the ETR performance we experienced in 2021. Focusing on the balance sheet, we ended the second quarter with $1.1 billion of cash and marketable securities and total debt of $13.4 billion. Approximately $450 million of debt was paid down in the quarter.
Turning to cash flow, our year-to-date cash from operations is $732 million. This performance reflects the results of net earnings and continued focus on working capital management, partially offset by the impact of higher costs for certain electronic components and pre-buying certain other critical raw material inventory. Considering our second quarter results, the strong order book for capital equipment and the sales momentum in our implant businesses, we now expect full-year 2022 organic sales growth to be in the range of 8% to 9%.
This performance assumes that the market environment experienced in Q2 continues to improve throughout the rest of the year with supply chain disruptions easing in the back half of the year. If foreign currency exchange rates hold near current levels, we expect net sales in the full year to be adversely impacted by approximately 2% to 3% and adjusted net earnings per diluted share to be adversely impacted by approximately $0.25 to $0.30 in the full year, which is included in our revised earnings guidance range.
Based on our performance in the second quarter, including consideration of the continued supply chain challenges and the inflationary environment together with our increased sales guidance and continued financial discipline and most significantly the anticipated future impact related to foreign currency, we now expect adjusted earnings to per share to be in the range of $9.30 to $9.50. The low end of this guidance range assumes that the continued macroeconomic volatility persists, including procedural disruptions and worsening of the electronic component availability. We will continue to evaluate the changing environment and we'll provide updates to our guidance as necessary.
And now I will open up the call for Q&A.